AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01175330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid
Description: Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
Study NCT01698554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost formulation A solution
Description: Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study NCT01698554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost solution 0.03 %
Description: Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study NCT01698554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of bimatoprost formulation A solution
Description: Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study NCT01698554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of bimatoprost solution 0.03 %
Description: Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study NCT00595140 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: pegvisomant
Description: growth hormone receptor antagonist pegvisomant in patients´ individual dose
Study NCT00595140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination with somatostatin analogue octreotide
Description: s.c., 100µg, one time
Study NCT00595140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination with dopamine agonist cabergoline
Description: oral, 0.5mg, one time
Study NCT03449225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Aided Genetic Education Module
Description: Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
Study NCT01670097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days.
Study NCT01670097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days.
Study NCT03220737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAXCHORA (Cholera Vaccine, Live, Oral)
Description: VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
Study NCT03220737 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VAXCHORA (Cholera Vaccine, Live, Oral)
Description: VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
Study NCT03220737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for this study is normal (0.9%) saline.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF Protein 150 mcg
Description: RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF 1*10^11 vp
Description: Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1\*10\^11 vp.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg
Description: Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg
Description: Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg
Description: Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg
Description: Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Selected Regimen
Description: A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
Study NCT01345461 — intervention group
Intervention type: DEVICE
Intervention: transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)
Description: two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
Study NCT03444688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation with walker
Description: For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
Study NCT03690323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
Study NCT03690323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
Study NCT02064725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium cridanimod
Description: Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
Study NCT03963479 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium and Vitamin B6
Description: Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
Study NCT03963479 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium and Vitamin B6
Description: Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
Study NCT03671538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
Study NCT03671538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
Study NCT03671538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
Study NCT00764842 — intervention group
Intervention type: DEVICE
Intervention: Encore CLP® Hip stem
Description: Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
Study NCT01051388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose PPI (Rabeprazole sodium)
Description: PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
Study NCT01051388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose PPI (Rabeprazole sodium)
Description: PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
Study NCT01051388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-PPI (Gefarnate)
Description: The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
Study NCT00592150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam
Description: The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
Study NCT00592150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion for 3 hours
Study NCT01286844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 5mg
Description: Oral powder for dispersion in water
Study NCT01286844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 10mg
Description: Oral powder for dispersion in water
Study NCT01286844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 25mg
Description: Oral powder for dispersion in water
Study NCT01286844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 50mg
Description: Oral powder for dispersion in water
Study NCT01286844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 100mg
Description: Oral powder for dispersion in water
Study NCT03290638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Description: Teeth Extraction With Bone Grafting and Membrane
Study NCT03690323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel plus Gemcitabine
Description: Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
Study NCT03690323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus Gemcitabine
Description: Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
Study NCT03290638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Description: Teeth Extraction With Bone Grafting and Membrane
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 10 mg/day
Description: During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
Study NCT01670097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
Study NCT01670097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
Study NCT01062399 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
Study NCT01670097 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
Study NCT01670097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometer
Description: Patient to blow into spirometry machine 1 time a day to test lung function.
Study NCT01670097 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spirometer
Description: Patient to blow into spirometry machine 1 time a day to test lung function.
Study NCT01670097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
Study NCT01670097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phone Calls
Description: Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
Study NCT04969562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
Study NCT03522649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
Study NCT03522649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
Study NCT03522649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
Study NCT03522649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
Study NCT03522649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
Study NCT00989443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir gel
Description: topical gel applied once a week for 3 weeks
Study NCT02985775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived CMVpp65-specific T cells
Description: About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
Study NCT03956082 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultravision™ Visual Field Clearing System
Description: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
Study NCT03956082 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultravision Ionwand™
Description: The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
Study NCT03404921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESTD
Description: During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
Study NCT03404921 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ESD
Description: The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
Study NCT00467597 — intervention group
Intervention type: DRUG
Intervention: Levodopa (delivered intravenously)
Description: IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit.
Study NCT03526484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
Study NCT03526484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
Study NCT02721563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Glycididazole
Description: Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
Study NCT02721563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
Study NCT03562182 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: Blood draw (2.5mL) to assess mRNA LPCAT1 levels
Study NCT03690323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
Study NCT03690323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
Study NCT00404703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg iv on day 1 of each 3 week cycle
Study NCT00404703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: As prescribed
Study NCT01962922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCP-Tacro
Description: once-daily extended release tablet
Study NCT01962922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus -IR
Description: twice daily capsules
Study NCT03932968 — intervention group
Intervention type: PROCEDURE
Intervention: pH-metry during 24 hours
Description: For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
Study NCT04128332 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Pre-operative stereotactic ablative body radiotherapy
Description: Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
Study NCT04661969 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
Study NCT01477203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 2-4 weeks, 5-10mg, max 20mg
Study NCT03777735 — intervention group
Intervention type: PROCEDURE
Intervention: human bone graft screw
Description: All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
Study NCT00568685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
Study NCT00568685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride
Description: Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period